首页> 外文期刊>Clinical oncology >Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium.
【24h】

Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium.

机译:FIGO I期子宫内膜癌的辅助放疗后的毒性,复发率和生存率。

获取原文
获取原文并翻译 | 示例
       

摘要

We conducted a retrospective observational study to determine the rate of toxicity, pattern of tumour recurrence and survival associated with radiotherapy treatment for FIGO stage I cancer of the endometrium. All patients had undergone definitive surgery and had been referred to the oncology department of the University Hospital Birmingham, U.K. Two hundred and forty-five women were included in the study; 228 patients were treated with radiotherapy; 160 had external beam radiation alone; 32 had vaginal vault brachytherapy alone; 36 patients had both modalities; and 17 patients were not given radiotherapy. There were nine cases of Grade 3 and 4 radiation reactions, of which four were acute, four were late and one was acute and late toxicity. The severity of both acute and late radiation effects was significantly associated with the delivery of vault brachytherapy (external beam radiotherapy alone compared with brachytherapy alone (1/158 vs 3/32; P = 0.02). Thirty-four patients were diagnosed with tumourrecurrence (11 distant, 14 local, 4 patients had both distant and local disease and 5 patients had recurrence diagnosed at the time of death). Patients who received no radiotherapy were at greater risk of local pelvic tumour recurrence (P < 0.0001; hazard ratio [HR] 9.6, 95% confidence interval (CI) 3.5-26.3). Vaginal vault brachytherapy had no discernible effect on the pattern of tumour recurrence. Forty-six patients died during the follow-up period, 28 of these were attributable to carcinoma of the endometrium. There was no difference in survival between the four treatment groups (P = 0.68). The overall 5-year survival rate in our study group was 89.6% (85.4-93.8%). In a proportional hazards model, tumour grade (HR 2.0 per level [1.25, 3.17]; P = 0.004]) and age (HR 1.74 per 10 years [1.12, 2.69]; P = 0.01) were the only factors found to have an independent influence on survival. This study suggests that, although pelvic radiation may not alter overall survival, it does reduce the risk of local disease recurrence. In this study population, vaginal vault brachytherapy using a vaginal stock/dobbie showed no additional benefits compared with external beam radiotherapy; it was, however, associated with a higher rate of both acute and late radiation effects.
机译:我们进行了一项回顾性观察性研究,以确定与子宫内膜FIGO I期癌症放疗相关的毒性率,肿瘤复发模式和生存率。所有患者均接受了明确的手术,并已转诊至英国伯明翰大学医院的肿瘤科。该研究纳入了245名女性; 228例患者接受了放疗。 160个具有单独的外部射线辐射; 32例仅接受了阴道穹顶近距离放射治疗;两种方式都有36例患者。 17例患者未接受放射治疗。有9例3级和4级放射反应,其中4例为急性,4例为晚期,1例为急性和晚期毒性。急性和晚期放疗的严重程度与穹顶近距离放疗的发生显着相关(单独的外部束放射治疗与单独的近距离放疗相比(1/158 vs 3/32; P = 0.02)。三十四例患者被诊断出肿瘤复发( 11例远处,14例局部,4例同时发生远处和局部疾病,5例在死亡时被诊断为复发。未接受放射治疗的患者骨盆局部肿瘤复发的风险更高(P <0.0001;危险比[HR ] 9.6,95%置信区间(CI)3.5-26.3)阴道穹ault近距离放疗对肿瘤的复发模式没有明显影响,在随访期间有46例患者死亡,其中28例归因于恶性肿瘤。子宫内膜;四个治疗组之间的生存率无差异(P = 0.68);我们研究组的总5年生存率是89.6%(85.4-93.8%)。每个2.0等级[1.25,3.17]; P = 0.004])和年龄(每10年HR 1.74 [1.12,2.69]; P = 0.01)是唯一对生存有独立影响的因素。这项研究表明,尽管骨盆辐射可能不会改变总体生存率,但确实降低了局部疾病复发的风险。在该研究人群中,与外部束放射疗法相比,使用阴道股/多比进行的阴道穹bra近距离放射治疗没有显示出其他益处。然而,这与急性和晚期放射效应的发生率较高有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号